Metabolic dysfunction-associated steatohepatitis (MASH) is often referred to as a “silent disease,” as it typically shows no signs of symptoms in early stages. But it can come with certain ...

Keep reading to learn about the link between obesity and MASH and how to reduce your risk of this disease. “MASH is a dysfunction of the liver caused by excess fat cells,” says Mir Ali ...

Opens in a new tab or window In patients with severe metabolic dysfunction-associated steatohepatitis (MASH), the investigational drug efruxifermin significantly improved fibrosis without ...

But one risk you may not be as familiar with is metabolic dysfunction–associated steatohepatitis (MASH). MASH is a type of liver inflammation and damage caused by a buildup of fat in the liver.

Last week's survey by the British Potato Council revealed that we prefer mash to chips. So is this good news for our health? Nutritionally speaking, both mash and chips are good sources of energy ...

At 10.30am on a chilly Saturday the queue outside Manze’s pie-and-mash shop on Deptford High Street stretches 50 metres down the street. The restaurant has been a fixture of the south-east ...

Potential competition from GLP-1 drugs and other MASH therapies exists, but REZDIFFRA's combination use and first-mover advantage mitigate these risks. Analysts project $515M in 2025 sales ...

At The BBC 1970-1988 features eleven discs of BBC sessions and a live DVD of Old Grey Whistle Test performances ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...